Anova Cancer Care Treats 1,000th Prostate Cancer Patient with the CyberKnife® System
For more information on the CyberKnife System, visit
For more information on the Anova Cancer Care visit https://anovacancercare.com/treatments/prostate-cancer/.
"Having treated 1,000 prostate cancer patients with CyberKnife SBRT, our clinical team understands first-hand the tremendous short and long-term advantages to patients receiving this treatment," said
Anova Cancer Care is an independent radiation therapy center dedicated to treating patients with benign and malignant tumors throughout the body. Of the 1,000 patients with prostate cancer treated at Anova, the control rate for the low-risk patients has been 100 percent and the typical intermediate-risk patients have been over 99 percent controlled. Several publications about the Anova experience with prostate cancer are being developed.
"I don't usually take the time to get yearly health exams but my wife insisted I get my
The prostate gland can move unpredictably throughout the course of treatment, making the ability to track, detect and correct for motion critically important. Unlike any other radiation delivery system, the CyberKnife® System continually tracks and automatically adjusts the beam for movement of the prostate in real-time throughout the entire treatment session. The System's accuracy is sub-millimeter -- its pinpoint precision is within the thickness of a dime, enhancing clinicians' ability to treat effectively while preserving healthy tissue.
"We commend Dr. Dickerson and the Anova team on the significant and positive impact they are having on the lives of men with prostate cancer. We are honored that our technology plays such a significant role in the great work they are doing," said
Published and ongoing studies of CyberKnife SBRT continue to validate this precise approach to the treatment of prostate cancer:
- The Registry for Prostate Cancer Radiosurgery, on which Dr. Dickerson serves on the board of directors, recently published data on 1,742 men from 45 clinics demonstrating excellent biochemical progression free survival and lack of significant side effects.
- At seven years, a study evaluating 477 men with low- or intermediate-risk cancer found these men experienced a high rate of biochemical progression free survival with acceptable toxicity and low
- A study of 1,100 men with low- or intermediate-risk prostate cancer showed an overall biochemical progression free survival of 93 percent at five years. Additionally,
PSArelapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients.2
- A prospective, multi-center study of 31 men with locally recurrent prostate cancer found use of SBRT as salvage therapy resulted in a biochemical free survival rate of 82 percent at two years with acceptable toxicity and low
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to future growth, market success, adoption of our new products or services, benefits of our technologies, and
Forward-looking statements speak only as of the date the statements are made and are based on information available to
1 Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol 2014;4:240.
2 King, C.R., "Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials." Radiother Oncol. 2013 Nov;109(2):217-21.
3 Fuller, D.B. et al. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment. Pract Radiat Oncol. 2015
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/anova-cancer-care-treats-1000th-prostate-cancer-patient-with-the-cyberknife-system-300157518.html
Beth Kaplan, Accuray, +1 (408) 789-4426, firstname.lastname@example.org, Kirsten Fallon, MSLGROUP in Boston, +1 (781) 684-0770, Kirsten.Fallon@MSLGROUP.com